“22q11.2 Deletion Syndrome Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the 22q11.2 Deletion Syndrome Market.
The 22q11.2 Deletion Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the 22q11.2 Deletion Syndrome Pipeline Report:
-
Companies across the globe are diligently working toward developing novel 22q11.2 Deletion Syndrome treatment therapies with a considerable amount of success over the years.
-
22q11.2 Deletion Syndrome companies working in the treatment market are Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others, are developing therapies for the 22q11.2 Deletion Syndrome treatment
-
Emerging 22q11.2 Deletion Syndrome therapies in the different phases of clinical trials are- ZYN002, NB-001, Metyrosine, and others are expected to have a significant impact on the 22q11.2 Deletion Syndrome market in the coming years.
-
In April 2024, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that Prenatal Diagnosis has published a study demonstrating an exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad’s prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. The study analyzed the PPV of detecting the 22q11.2 microdeletion using non-invasive prenatal cfDNA screening that includes fetal-fraction amplification.
-
In December 2023, Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases, will present caregiver-reported impacts of 22q11.2 deletion syndrome (22q) and data from the Phase 2 INSPIRE trial.
22q11.2 Deletion Syndrome Overview
22q11.2 deletion syndrome, also known as DiGeorge syndrome, velocardiofacial syndrome, or simply 22q11.2DS, is a genetic disorder caused by a small missing piece of chromosome 22. This syndrome can lead to a variety of health and developmental issues.
Get a Free Sample PDF Report to know more about 22q11.2 Deletion Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/22q112-deletion-syndrome-pipeline-insight
Emerging 22q11.2 Deletion Syndrome Drugs Under Different Phases of Clinical Development Include:
-
ZYN002: Zynerba Pharmaceuticals, Inc.
-
NB-001: Nobias Therapeutics, Inc.
-
Metyrosine: Bausch Health Americas, Inc.
22q11.2 Deletion Syndrome Route of Administration
22q11.2 Deletion Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
22q11.2 Deletion Syndrome Molecule Type
22q11.2 Deletion Syndrome Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
22q11.2 Deletion Syndrome Pipeline Therapeutics Assessment
-
22q11.2 Deletion Syndrome Assessment by Product Type
-
22q11.2 Deletion Syndrome By Stage and Product Type
-
22q11.2 Deletion Syndrome Assessment by Route of Administration
-
22q11.2 Deletion Syndrome By Stage and Route of Administration
-
22q11.2 Deletion Syndrome Assessment by Molecule Type
-
22q11.2 Deletion Syndrome by Stage and Molecule Type
DelveInsight’s 22q11.2 Deletion Syndrome Report covers around 5+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further 22q11.2 Deletion Syndrome product details are provided in the report. Download the 22q11.2 Deletion Syndrome pipeline report to learn more about the emerging 22q11.2 Deletion Syndrome therapies
Some of the key companies in the 22q11.2 Deletion Syndrome Therapeutics Market include:
Key companies developing therapies for 22q11.2 Deletion Syndrome are – Zynerba Pharmaceuticals, Enzyvant, Roivant Sciences, Sumitomo Dainippon Pharma, and others.
22q11.2 Deletion Syndrome Pipeline Analysis:
The 22q11.2 Deletion Syndrome pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of 22q11.2 Deletion Syndrome with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for 22q11.2 Deletion Syndrome Treatment.
-
22q11.2 Deletion Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
22q11.2 Deletion Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the 22q11.2 Deletion Syndrome market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about 22q11.2 Deletion Syndrome drugs and therapies
22q11.2 Deletion Syndrome Pipeline Market Strengths
-
22q11.2 deletion syndrome is a rare genetic condition; thus, companies developing treatment options for the same can possess several advantages like 7-year market exclusivity, orphan drug designation, and others.
22q11.2 Deletion Syndrome Pipeline Market Opportunities
-
There exists no approved treatment for the syndrome, as a result, there are several chances for the companies to investigate unmet requirements and develop therapeutic choices that will benefit the patient population and leverage this prevalent orphan indication
Scope of 22q11.2 Deletion Syndrome Pipeline Drug Insight
-
Coverage: Global
-
Key 22q11.2 Deletion Syndrome Companies: Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others
-
Key 22q11.2 Deletion Syndrome Therapies: ZYN002, NB-001, Metyrosine, and others
-
22q11.2 Deletion Syndrome Therapeutic Assessment: 22q11.2 Deletion Syndrome current marketed and 22q11.2 Deletion Syndrome emerging therapies
-
22q11.2 Deletion Syndrome Market Dynamics: 22q11.2 Deletion Syndrome market drivers and 22q11.2 Deletion Syndrome market barriers
Request for Sample PDF Report for 22q11.2 Deletion Syndrome Pipeline Assessment and clinical trials
Table of Contents
1. 22q11.2 Deletion Syndrome Report Introduction
2. 22q11.2 Deletion Syndrome Executive Summary
3. 22q11.2 Deletion Syndrome Overview
4. 22q11.2 Deletion Syndrome- Analytical Perspective In-depth Commercial Assessment
5. 22q11.2 Deletion Syndrome Pipeline Therapeutics
6. 22q11.2 Deletion Syndrome Late Stage Products (Phase II/III)
7. 22q11.2 Deletion Syndrome Mid Stage Products (Phase II)
8. 22q11.2 Deletion Syndrome Early Stage Products (Phase I)
9. 22q11.2 Deletion Syndrome Preclinical Stage Products
10. 22q11.2 Deletion Syndrome Therapeutics Assessment
11. 22q11.2 Deletion Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. 22q11.2 Deletion Syndrome Key Companies
14. 22q11.2 Deletion Syndrome Key Products
15. 22q11.2 Deletion Syndrome Unmet Needs
16 . 22q11.2 Deletion Syndrome Market Drivers and Barriers
17. 22q11.2 Deletion Syndrome Future Perspectives and Conclusion
18. 22q11.2 Deletion Syndrome Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: 22q11.2 Deletion Syndrome Pipeline Assessment 2024: Therapies, Clinical Trials, FDA Approvals by DelveInsight | Zynerba Pharma, Enzyvant, Roivant Sciences, Sumitomo Dainippon Pharma
![LinQ raises [$3.8M] to propel top mobile game publishers in the RMG arena](https://www.getnews.info/wp-content/uploads/2024/06/1719449855.png "LinQ raises [$3.8M] to propel top mobile game publishers in the RMG arena")
